{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T06:18:41Z","timestamp":1777357121062,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Natural Science Foundation","award":["Grant No. Z200015"],"award-info":[{"award-number":["Grant No. Z200015"]}]},{"name":"Beijing Municipal Administration of Hospitals Incubating Program","award":["Grant No. PX2020046"],"award-info":[{"award-number":["Grant No. PX2020046"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["Grant Nos. 91959116 and 81971584"],"award-info":[{"award-number":["Grant Nos. 91959116 and 81971584"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["Grant No. ZYLX201803"],"award-info":[{"award-number":["Grant No. ZYLX201803"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority Ascent Plan","award":["Grant No. 20191103"],"award-info":[{"award-number":["Grant No. 20191103"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>To investigate the performance of quantitative CT analysis in predicting the prognosis of patients with locally advanced oesophageal squamous cell carcinoma (ESCC) after two cycles of induction chemotherapy before definitive chemoradiotherapy\/radiotherapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 110 patients with locally advanced ESCC were retrospectively analysed. Baseline chest CT and CT after two cycles of induction chemotherapy were analysed. A multivariate Cox proportional-hazard regression model was used to identify independent prognostic markers for survival analysis. Then, a CT scoring system was established. Time-dependent receiver operating characteristic (ROC) curve analysis and the Kaplan-Meier method were employed for analysing the prognostic value of the CT scoring system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Body mass index, treatment strategy, change ratios of thickness (\u0394TH<jats:sub>max<\/jats:sub>), CT value of the primary tumour (\u0394CTV<jats:sub>axial<\/jats:sub>) and the short diameter (\u0394SD-LN), and the presence of an enlarged small lymph node (ESLN) after two cycles of chemotherapy were noted as independent factors for predicting overall survival (OS). The specificity of the presence of ESLN for death after 12 months was up to 100%. Areas under the curve value of the CT scoring system for predicting OS and progression-free survival (PFS) were higher than that of the RECIST (<jats:italic>p<\/jats:italic> &lt; 0.05). Responders had significantly longer OS and PFS than non-responders.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Quantitative CT analysis after two cycles of induction chemotherapy could predict the outcome of locally advanced ESCC patients treated with definitive chemoradiotherapy\/radiotherapy. The CT scoring system could contribute to the development of an appropriate strategy for patients with locally advanced ESCC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:italic>\u2022 Quantitative CT evaluation after two cycles of induction chemotherapy can predict the long-term outcome of locally advanced oesophageal cancer treated with definitive chemoradiotherapy\/radiotherapy.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 A CT scoring system provides valuable imaging support for indicating the prognosis at the early stage of therapy.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 Quantitative CT evaluation can assist clinicians in personalising treatment plans.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-022-08994-y","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T16:02:50Z","timestamp":1659628970000},"page":"380-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quantitative CT evaluation after two cycles of induction chemotherapy to predict prognosis of patients with locally advanced oesophageal squamous cell carcinoma before undergoing definitive chemoradiotherapy\/radiotherapy"],"prefix":"10.1007","volume":"33","author":[{"given":"Shuo","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Jie","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Yuan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Hao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9424-1910","authenticated-orcid":false,"given":"Ying-Shi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"8994_CR1","unstructured":"World Health Organization (2020) Global Cancer Observatory: cancer today. World Health Organization, Geneva. Available via https:\/\/gco.iarc.fr\/today. Accessed 18 June 2021"},{"key":"8994_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/dote\/dox075","volume":"30","author":"A Okamura","year":"2017","unstructured":"Okamura A, Watanabe M, Mine S et al (2017) Failure of neoadjuvant chemotherapy for resectable esophageal squamous cell carcinoma. Dis Esophagus 30:1\u20138","journal-title":"Dis Esophagus"},{"key":"8994_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00066-017-1211-0","volume":"194","author":"MF Haefner","year":"2018","unstructured":"Haefner MF, Lang K, Verma V et al (2018) Neoadjuvant versus definitive chemoradiotherapy for locally advanced esophageal cancer: outcomes and patterns of failure. Strahlenther Onkol 194:116\u2013124","journal-title":"Strahlenther Onkol"},{"key":"8994_CR4","doi-asserted-by":"publisher","first-page":"5881","DOI":"10.1002\/cam4.3273","volume":"9","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Zhang Y, Wang X, Geng X, Zhu L, Li M (2020) Clinical response to chemoradiotherapy in esophageal carcinoma is associated with survival and benefit of consolidation chemotherapy. Cancer Med 9:5881\u20135888","journal-title":"Cancer Med"},{"key":"8994_CR5","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/14737140.2020.1814149","volume":"20","author":"H Imazeki","year":"2020","unstructured":"Imazeki H, Kato K (2020) Development of chemotherapeutics for unresectable advanced esophageal cancer. Expert Rev Anticancer Ther 20:1083\u20131092","journal-title":"Expert Rev Anticancer Ther"},{"key":"8994_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/jjco\/hyz034","volume":"49","author":"H Hirano","year":"2019","unstructured":"Hirano H, Kato K (2019) Systemic treatment of advanced esophageal squamous cell carcinoma: chemotherapy, molecular-targeting therapy and immunotherapy. Jpn J Clin Oncol 49:412\u2013420","journal-title":"Jpn J Clin Oncol"},{"key":"8994_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s00268-001-0271-5","volume":"26","author":"W Schr\u00f6der","year":"2002","unstructured":"Schr\u00f6der W, Baldus SE, M\u00f6nig SP, Beckurts TK, Dienes HP, H\u00f6lscher AH (2002) Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg 26:584\u2013587","journal-title":"World J Surg"},{"key":"8994_CR8","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1245\/s10434-013-2946-1","volume":"20","author":"Y Kurokawa","year":"2013","unstructured":"Kurokawa Y, Shibata T, Ando N, Seki S, Mukaida H, Fukuda H (2013) Which is the optimal response criteria for evaluating preoperative treatment in esophageal cancer: RECIST or histology? Ann Surg Oncol 20:3009\u20133014","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 3","key":"8994_CR9","doi-asserted-by":"publisher","first-page":"S1380","DOI":"10.1245\/s10434-015-4531-2","volume":"22","author":"XY Zhang","year":"2015","unstructured":"Zhang XY, Yan WP, Sun Y et al (2015) CT signs can predict treatment response and long-term survival: a study in locally advanced esophageal cancer with preoperative chemotherapy. Ann Surg Oncol 22(Suppl 3):S1380\u2013S1387","journal-title":"Ann Surg Oncol"},{"key":"8994_CR10","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1007\/s00261-019-01911-w","volume":"44","author":"A Djuric-Stefanovic","year":"2019","unstructured":"Djuric-Stefanovic A, Jankovic A, Saponjski D et al (2019) Analyzing the post-contrast attenuation of the esophageal wall on routine contrast-enhanced MDCT examination can improve the diagnostic accuracy in response evaluation of the squamous cell esophageal carcinoma to neoadjuvant chemoradiotherapy in comparison with the esophageal wall thickness. Abdom Radiol (NY) 44:1722\u20131733","journal-title":"Abdom Radiol (NY)"},{"key":"8994_CR11","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/SLA.0000000000003445","volume":"273","author":"S Urakawa","year":"2019","unstructured":"Urakawa S, Makino T, Yamasaki M et al (2019) Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in metastatic esophageal cancer. Ann Surg. 273:1141\u20131149","journal-title":"Ann Surg."},{"key":"8994_CR12","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.1007\/s00330-019-06310-9","volume":"29","author":"JM Findlay","year":"2019","unstructured":"Findlay JM, Dickson E, Fiorani C et al (2019) Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. Eur Radiol 29:6717\u20136727","journal-title":"Eur Radiol"},{"key":"8994_CR13","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1148\/rg.346130079","volume":"34","author":"SJ Hong","year":"2014","unstructured":"Hong SJ, Kim TJ, Nam KB et al (2014) New TNM staging system for esophageal cancer: what chest radiologists need to know. Radiographics 34:1722\u20131740","journal-title":"Radiographics"},{"key":"8994_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jtho.2016.10.016","volume":"12","author":"TW Rice","year":"2017","unstructured":"Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P (2017) Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol 12:36\u201342","journal-title":"J Thorac Oncol"},{"key":"8994_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247","journal-title":"Eur J Cancer"},{"key":"8994_CR16","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/sim.1742","volume":"23","author":"LM Sullivan","year":"2004","unstructured":"Sullivan LM, Massaro JM, D'Agostino RB Sr (2004) Presentation of multivariate data for clinical use: the Framingham Study risk score functions. Stat Med 23:1631\u20131660","journal-title":"Stat Med"},{"key":"8994_CR17","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1093\/ejcts\/ezs136","volume":"42","author":"SH Li","year":"2012","unstructured":"Li SH, Rau KM, Lu HI et al (2012) Pre-treatment maximal oesophageal wall thickness is independently associated with response to chemoradiotherapy in patients with T3-4 oesophageal squamous cell carcinoma. Eur J Cardiothorac Surg 42:958\u2013964","journal-title":"Eur J Cardiothorac Surg"},{"issue":"1152-1160","key":"8994_CR18","doi-asserted-by":"crossref","first-page":"discussion 1152","DOI":"10.1016\/j.athoracsur.2004.04.046","volume":"78","author":"SG Swisher","year":"2004","unstructured":"Swisher SG, Maish M, Erasmus JJ et al (2004) Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 78(1152-1160):discussion 1152-1160","journal-title":"Ann Thorac Surg"},{"key":"8994_CR19","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.2147\/CMAR.S295646","volume":"13","author":"Y Wu","year":"2021","unstructured":"Wu Y, Li J (2021) Change in maximal esophageal wall thickness provides prediction of survival and recurrence in patients with esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy and surgery. Cancer Manag Res 13:2433\u20132445","journal-title":"Cancer Manag Res"},{"key":"8994_CR20","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N et al (2005) Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23:2310\u20132317","journal-title":"J Clin Oncol"},{"key":"8994_CR21","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/cncr.10868","volume":"95","author":"MA Eloubeidi","year":"2002","unstructured":"Eloubeidi MA, Desmond R, Arguedas MR, Reed CE, Wilcox CM (2002) Prognostic factors for the survival of patients with esophageal carcinoma in the U.S.: the importance of tumor length and lymph node status. Cancer 95:1434\u20131443","journal-title":"Cancer"},{"key":"8994_CR22","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1442-2050.2011.01195.x","volume":"24","author":"WL Chang","year":"2011","unstructured":"Chang WL, Lin FC, Yen CJ et al (2011) Tumor length assessed by miniprobe endosonography can predict the survival of the advanced esophageal squamous cell carcinoma with stricture receiving concurrent chemoradiation. Dis Esophagus 24:590\u2013595","journal-title":"Dis Esophagus"},{"key":"8994_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ygyno.2021.06.025","volume":"162","author":"L Benoit","year":"2021","unstructured":"Benoit L, Zerbib J, Koual M et al (2021) What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery? Gynecol Oncol. 162:667\u2013673","journal-title":"Gynecol Oncol."},{"key":"8994_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1001\/jamaoncol.2021.2705","volume":"7","author":"Y Ji","year":"2021","unstructured":"Ji Y, Du X, Zhu W et al (2021) Efficacy of concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: a multicenter randomized phase 3 clinical trial. JAMA Oncol 7:1459\u20131466","journal-title":"JAMA Oncol"},{"key":"8994_CR25","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1634\/theoncologist.2018-0143","volume":"23","author":"ME Salem","year":"2018","unstructured":"Salem ME, Puccini A, Xiu J et al (2018) Comparative molecular analyses of esophageal squamous cell carcinoma, esophageal adenocarcinoma, and gastric adenocarcinoma. Oncologist 23:1319\u20131327","journal-title":"Oncologist"},{"key":"8994_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"Cancer Genome Atlas Research N, Analysis Working Group: Asan U, BC Cancer Agency et al","year":"2017","unstructured":"Cancer Genome Atlas Research N, Analysis Working Group: Asan U, BC Cancer Agency et al (2017) Integrated genomic characterization of oesophageal carcinoma. Nature 541:169\u2013175","journal-title":"Nature"},{"key":"8994_CR27","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090\u20131098","journal-title":"Lancet Oncol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-08994-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-08994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T12:16:48Z","timestamp":1671106608000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-08994-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["8994"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-08994-y","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"16 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Ying-Shi Sun.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board for this retrospective study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}